Excessive weight gain has been identified as a serious metabolic side-effect of second-generation antipsychotics (SGAs), including olanzapine. While hyperphagia has been suggested to be the main contributor for this sideeffect in the short term, reduced energy expenditure, in particular thermogenesis and locomotor activity, has been considered to contribute to the maintenance of heavy weight under long-term SGA treatments. Recent studies have identified metabolically active brown adipose tissues (BAT) in adult humans, suggesting potential clinical significance for the involvement of BAT thermogenesis in SGA-induced weight gain. However, to date there has been little research elucidating the central neuronal pathways affecting BAT thermogenesis or the morphological changes of the BAT. The present study aimed to investigate the role of BAT thermogenesis and locomotor activity in olanzapine-induced weight gain during the prolonged time courses of olanzapine treatment in an established female rat model. Although short-to mid-term olanzapine treatment had no effect on BAT temperature, we observed that long-term olanzapine treatment (from day 18 to 34) induced a significant reduction in BAT temperature, with an acute effect being observed between 45 and 150 min post-treatment in the longterm cohort. Additionally, in the long-term olanzapine group, the reduced BAT temperature was accompanied by decreased UCP1 and PGC-1α expressions in the BAT. Moreover, TH mRNA expressions in both hypothalamus and brainstem were also downregulated after mid-to long-term olanzapine treatment. Further, olanzapine led to reduced percentage of brown adipocytes in BAT during mid-to long-term treatments. Finally, locomotor activity was reduced throughout the three treatment cohorts. In summary, our results suggest that the reduction of BAT thermogenesis plays an important role during the long-term of olanzapine-induced weight gain, which was accompanied by an earlier onset of BAT adipocyte morphological changes and biochemical changes in the hypothalamus and the brainstem, while locomotor activity contributes to the entire olanzapine treatment courses.
Introduction
While second-generation antipsychotics (SGAs) have been widely prescribed as the primary treatment for patients with schizophrenia and other psychiatric diseases, excessive body weight gain associated with the use of SGAs, in particular olanzapine and clozapine, has attracted increasing concerns from patients, clinicians, and medical researchers (Zhang et al., 2013) . This weight gain side-effect of SGAs, along with other metabolic side-effects, could lead to increased morbidity and mortality, and poor compliance to the antipsychotic drug for patients (Deng, 2013) .
Both clinical and animal studies have suggested that along the time course of olanzapine-induced weight gain, there are three typical stages: the initial stage with rapid increase of body weight accompanied with elevated food intake, the middle stage with slow body weight gain and no elevation of food intake, and the late stage with maintenance of the heavy body weight without elevated food intake (Huang et al., 2006; Pai et al., 2012) . In recent years, researchers have identified multiple contributing factors for the weight gain side-effect induced by SGAs (Kroeze et al., 2003; Nasrallah, 2008; Reynolds and Kirk, 2010) . Abbreviations: BAT, brown adipose tissue; IBAT, interscapular brown adipose tissue; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator-1α; qRT-PCR, quantitative real-time PCR; SGAs, second-generation antipsychotics; TH, tyrosine hydroxylase; UCP1, uncoupling protein1.
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